AstraZeneca Set to Buy More Chinese Drugs (China)
This article was originally published in PharmAsia News
Executive SummaryAstraZeneca has announced it will join the ranks of drug manufacturers choosing to obtain raw materials and active pharmaceutical ingredients from emerging Asian markets. Over the next three years, the company's Chinese contracts will grow from $10 million to $100 million. AstraZeneca has also announced intentions to enact a similar investment plan in India's drug manufacturing industry. The company's move is part of a larger goal to reduce drug production costs, in an effort to keep business lucrative. The industry's renewed respect for the bottom line comes as the result of fierce generic competition and dwindling global patent protection for brand-name drugs. Still, many companies are daunted by a lack of production safety standards and intellectual property rights in some countries. But the promise of improvements in regulatory conditions are making outsourcing to countries like China and India a hard deal for manufacturers to resist. (Click here for more - May Require Paid Subscription
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.